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Immunisation registers are regarded as an appropriate 
solution to measure vaccination coverage on a popu-
lation level. In Germany, a decentralised healthcare 
system and data protection regulations constrain such 
an approach. Moreover, shared responsibilities in the 
process of immunisation and multiple providers form 
the framework for public health interventions on vac-
cination issues. On the national level, those interven-
tions consist mainly of conceptualising immunisation 
strategies, establishing vaccination programmes, 
and issuing recommendations. This paper provides 
an overview on sources and methods for collecting 
appropriate coverage data at national level and their 
public health relevance in Germany. Methods of data 
collection and available information on immunisations 
are described for three approaches: school entrance 
health examination, population surveys and insurance 
refund claim data. School entrance health examina-
tions allow regional comparisons and estimation of 
trends for a specific cohort of children and for all rec-
ommended childhood vaccinations. Surveys deliver 
population based data on completeness and timeliness 
of selected vaccinations in populations defined by age 
or socio-demographic parameters and on knowledge 
and attitudes towards vaccination. Insurance refund 
claim data inform continuously on immunisation sta-
tus (e.g. of children aged two years) or on vaccination 
incidence promptly after new or modified recommen-
dations. In a complex healthcare system, the German 
National Public Health Institute (Robert Koch Institute, 
RKI) successfully compiles coverage data from dif-
ferent sources, which complement and validate one 
another. With the German approach of combining dif-
ferent data sources in the absence of immunisation 
registers, it is possible to gain solid and reliable data 
on the acceptance of vaccination programmes and tar-
get groups for immunisation. This approach might be 
of value for other countries with decentralised health-
care systems.
Introduction
Germany has a population of 82 million people living 
in 16 federal states. Health legislation with regard to 
communicable diseases is national and recommen-
dations on vaccination are released annually by the 
German Standing Committee on Vaccination (STIKO) 
[1,2]. STIKO recommendations are not legally binding 
but are usually closely complied with or complemented 
by the official recommendations of the federal states. 
The official recommendation is necessary for receiv-
ing compensation in case of adverse events following 
immunisation. STIKO recommendations are the basis 
for the decision by the Joint Federal Committee (self-
governing body of physicians and health insurance 
funds), whether the costs of vaccinations are covered 
by the statutory health insurances. In Germany, health 
insurance is obligatory. The majority (85%) of people 
living in Germany are members of a variety of statutory 
health insurances, all of which provide a basic health-
care plan by statute and are funded by fixed fees paid 
by the members and their employers. The remaining 
15% are mainly insured with private health insurance 
companies. 
STIKO recommendations do not include specific vac-
cines but antigens and refer to specific target groups 
(defined by age, risk etc.). Beyond recommendations, 
all licensed vaccines can be administered, but have to 
be paid by the patients at their own expense. 
Vaccination is voluntary in Germany. People are not 
only free to decide whether or not they get vaccinated 
but also which physician they want to consult. 
Private physicians administer about 90% of all vac-
cinations and may choose from all available vaccines 
that are licensed. The remaining 10% are given in pub-
lic health clinics, schools, or day care centres through 
special programmes of the federal states or by occu-
pational health physicians [3]. Every vaccination has 
to be documented in the vaccination card of the vac-
cinee. Documentation includes antigen, brand name, 
batch number, and application date. The administering 
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physician enters the same information into his patient 
file. Vaccination cards and files are not centrally 
registered.
The decentralised healthcare system together with 
data protection regulations which emphasise every-
one’s right to a self-determined use of personal data 
[4], are strong constraints for national registers. In only 
one German federal state, all vaccinations of children 
up to the age of seven are to be reported to the local 
public health services by law. However, informed con-
sent of the parents is required prior to reporting and 
regulations concerning how these data should be reg-
istered and processed are lacking [5].
As vaccinations affect health at individual and popula-
tion level, the assessment and evaluation of trends and 
of regional and demographic differences in vaccination 
coverage are major public health tasks. At the level 
of the federal states, the commitment to these tasks 
and their prioritisation vary and range from state cam-
paigns and intensive monitoring of immunisation to 
leaving all action to the capacities and responsibility 
of the local health offices.
At national level, the development of immunisation 
strategies, the establishment of vaccination pro-
grammes, and the evaluation of recommendations are 
the main tasks requiring reliable and representative 
data on vaccination coverage. The Robert Koch Institute 
(RKI) as the German National Public Health Institute 
in the portfolio of the German Ministry of Health is 
responsible for collection and analysis of these data. 
This paper provides an overview on sources and meth-
ods used by the RKI for collecting appropriate cover-
age data at national level in the context of the German 
healthcare system and with regard to their public 
health relevance.
Methods
The RKI uses primary and secondary data to monitor 
the uptake of vaccines and to evaluate vaccination 
programmes. While primary data refer directly to the 
immunisation status as measured in, documented for 
or remembered by the respective individual, second-
ary data are obtained from sources with an original 
purpose different from assessing immunisation status 
or coverage. Primary data on vaccination coverage are 
gathered by the assessment of vaccination cards of 
children prior to school entry or by population surveys 
[6]. Secondary sources of information on vaccinations 
are data originating from physicians’ refund claims 
from health insurances [6]. 
School entrance health examination
The Communicable diseases Law Reform Act 
(Infektionsschutzgesetz, IfSG) [7] requires to collect the 
vaccination status at school entry and to send aggre-
gated coverage data to the RKI. Health examinations 
are carried out as a precondition for school entrance 
and concern children whose age varies from four to six 
years, depending on the federal state. The school entry 
cohort includes children, who should have completed 
their primary vaccination courses. Part of the exami-
nation is to check the completeness of recommended 
childhood vaccinations as documented in the vacci-
nation card and give individual catch-up reminders 
where necessary. The school entrance health exami-
nations (SEE) are carried out locally, vaccination data 
are aggregated at county level and sent to the federal 
state. Data are then transferred to the RKI once a year 
and include the number of investigated children, the 
number of children presenting the vaccination cards 
and the number of fully and of partly vaccinated chil-
dren by defined antigens per federal state. Vaccination 
coverage of the respective school entry cohort is cal-
culated based on children presenting their vaccination 
cards and the results, stratified by federal states, are 
published by the RKI in the Epidemiological Bulletin 
annually [8]. 
Population surveys
The RKI regularly conducts health examination surveys 
and health interview surveys, which are described in 
more detail below. These surveys both include cross-
sectional and longitudinal components in subsequent 
follow-ups, and are periodically carried out. The study 
population is geographically and socio-economically 
representative for the German population [9]. According 
to pre-defined sampling procedures, people are invited 
either to present to dedicated study units (for health 
examination and face-to-face interview) or to be inter-
viewed by phone only (interview survey). Both forms – 
health examination including health interview as well 
as health interview only – are alternately conducted. 
Vaccination status is included into these surveys as 
one of multiple core indicators of the population’s 
health status. It is assessed for selected antigens on 
the basis of either vaccination cards or reports by the 
subjects themselves. In the health examination sur-
veys, data is complemented by serological testing for 
specific antibody. 
The health examination and interview surveys for chil-
dren and adolescents are conducted separately from 
that for adults. The nationwide representative ’German 
Health Interview and Examination Survey for Children 
and Adolescents‘ (KiGGS) was carried out between 
May 2003 and May 2006. KiGGS was based on a sam-
ple of 17,641 children and adolescents aged 0–17 years 
with main residence in Germany. The ’German Health 
Interview and Examination Survey for Adults‘ (DEGS) 
is the respective representative survey for adults con-
ducted by the RKI, succeeding previous adult surveys, 
the last of which was in the late 1990s. The DEGS 
was carried out from November 2008 until November 
2011 in a total of 180 cities and municipalities all over 
Germany and included 7,988 adults aged 18–79 years. 
Like in KiGGS, in DEGS vaccination cards and serologi-
cal tests are used to assess the immune status.
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The examination survey is periodically accompanied by 
the ’German Health Update‘ (GEDA) by waves of tele-
phone surveys which started in July 2008 and involved 
already 25,000 and 23,000 people aged 18 years 
and over in 2008–09 and in 2009–10, respectively. 
Questions on vaccination status for influenza, tetanus 
and pertussis were included into the interviews [10].
Additional sporadic and smaller surveys for defined 
research questions are conducted by the RKI to gather 
information on knowledge, attitude and behaviour 
towards vaccination in the general population or in 
defined groups. For example, during the 2009/10 influ-
enza season, uptake of seasonal and influenza A(H1N1)
pdm09 vaccines as well as acceptance and progress 
of the pandemic influenza vaccination campaign was 
monitored by consecutive representative surveys. 
The RKI commissioned a professional market research 
agency to carry out computer assisted telephone inter-
views (CATI) by experienced interviewers [11]. 
Insurance refund claim data
Statutory Health Insurance Funds are billed by the 
Associations of Statutory Health Insurance Physicians 
(ASHIP) on the basis of quarterly reports on medical 
services, including vaccinations, delivered by physi-
cians. ASHIPs are regionally organised, mostly one 
ASHIP per federal state. In 2004, the RKI established an 
ongoing project together with ASHIPs using their insur-
ance refund claim data for epidemiological assessment 
of vaccine preventable diseases and vaccination cover-
age. The methods of the project, including a detailed 
description of quality assurance have been described 
elsewhere [12]. Pseudonymised data are quarterly 
transmitted from the ASHIPs to the RKI and include 
demographic characteristics of the vaccinees (month 
and year of birth, sex, county of residence), informa-
tion on the vaccination (vaccine, date of vaccination), 
and information on medical contacts (medical speciali-
sation of physician, county of physician’s office). 
According to the public health question of interest, 
different applications of these data are possible for 
monitoring vaccination coverage, i.e. follow-up of birth 
cohorts and vaccination incidence. Information on dis-
tinct individuals can be tracked over time for receiving 
vaccinations. Thus, birth cohorts can be followed-up 
and compared by vaccination status at a certain age 
(i.e. 24 months) and by ASHIP region [13]. 
Vaccination incidence is defined as the number of vac-
cinated individuals in relation to the number of insured 
individuals of the same age and per time. Taking into 
account that the number of vaccinated persons accu-
mulates over time, the cumulative vaccination inci-
dence by a defined age and year can be calculated. 
We used the insurance refund claim data and the meth-
ods described to determine varicella vaccine cover-
age. Varicella vaccination is part of the recommended 
childhood immunisation schedule since 2004. It was 
therefore not included in KiGGS and firstly recorded at 
SEE in 2008.
Results
In the following sections only selected results of the 
above described methods are shown as example of 
their feasibility and practical use. 
School entrance health examination
With more than 90% in total, the vast majority of chil-
dren had vaccination cards available at SEE 2009. 
While the percentage of children having their vaccina-
tion cards has increased over time, the range between 
the federal states’ highest and lowest value has 
decreased, however the minimum was still below 90% 
in 2009. 
SEE for 2009 showed, that vaccination coverage of chil-
dren fully immunised against diphtheria, tetanus, polio 
(>95% each) and Haemophilus influenzae type b (Hib, 
94%) was high [8]. Figure 1 shows the vaccination cov-
erage for selected antigens. Immunisation gaps existed 
particularly for hepatitis B (90% coverage) and for the 
second dose of measles (90%). Moreover, increasing 
vaccine uptake was visible in recent years, especially 
for the second dose of vaccines containing measles 
antigens. Data on varicella vaccination in 2009 were 
available from 15 federal states and varied between 
15% and 71%. For almost all vaccinations, SEE-data 
analysis also revealed a higher coverage in eastern 
federal states (Saxony, Brandenburg, Saxony-Anhalt, 
Thuringia, Mecklenburg-West Pomerania, n=5) than 
in western federal states (North Rhine-Westphalia, 
Bavaria, Baden-Württemberg, Hesse, Lower Saxony, 
Rhineland-Palatinate, Berlin, Hamburg, Schleswig-
Holstein, Saarland, Bremen, n=11). 
Population surveys
According to KiGGS, the average prevalence of com-
pleted immunisation series for tetanus, diphtheria and 
polio as well as the coverage for the first dose of mea-
sles vaccination was above 90% in children aged 2–17 
years. Primary courses were often not completed at the 
recommended age of two years. Vaccination coverage 
for pertussis, Hib and hepatitis B was higher in younger 
children than in adolescents [14]. Multivariate analy-
ses revealed predictors for not being vaccinated or for 
negative serology i.e. regarding measles, such as born 
abroad and critical attitudes of parents towards vacci-
nation [14,15]. Children not presenting the vaccination 
cards were more likely to be seronegative. 
First results of GEDA revealed immunisation gaps for 
tetanus of more than 25% in the adult population [16].
About 1,000 randomly selected German speak-
ing persons aged 14 years or older, living in private 
households, were included in each of the consecutive 
bi-weekly telephone surveys on the influenza A(H1N1)
pdm09 vaccine, during the influenza season 2009/10, 
so that by week 53 in 2009, a total of 4,003 people had 
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been interviewed. Vaccination coverage was shown to 
be low reaching only 8% at the end of December 2009 
(Figure 2) [11]. 
Insurance refund claim data
For one dose of varicella vaccine, coverage at two years 
of age was 34% for birth cohort 2004 and differed 
regionally between 13 examined ASHIPs [13]. Children 
of birth cohort 2005 were the first to be vaccinated 
with two doses of a combined vaccine against measles, 
mumps, rubella and varicella (MMRV) at two years of 
age. The varicella coverage for birth cohort 2005 was 
51%, including 5% of children who received two doses 
of MMRV. For birth cohort 2007, preliminary analysis of 
data from six ASHIPs showed a further increase of cov-
erage with one dose of varicella vaccine at two years of 
age to >80% (unpublished data). 
Annual vaccination incidence for one dose of vari-
cella vaccine was highest in one year old children and 
increased here from 4% in 2004 to 50% in 2006 (Figure 
3). Cumulative vaccination incidence for the age group 
comprising four to six year-olds increased from 1% to 
47% between 2004 and 2009.
Discussion
For the estimation of vaccination coverage at national 
level vaccination data as retrieved at SEE are the only 
routine data required by law (IfSG) in Germany [7]. 
Based on SEE coverage across regions can be com-
pared and trends for complete cohorts can be assessed 
by all recommended childhood vaccinations. Thus, rep-
resentativeness, completeness and validity are high. 
However, shortcomings of this approach are that time-
liness of vaccination cannot be assessed at national 
level and that vaccinations which are newly introduced 
into the childhood immunisation schedule are eligi-
ble for assessment at school entry only several years 
thereafter. For example, since its recommendation in 
2004, varicella vaccination coverage was still not avail-
able from all federal states for the school-entry cohort 
2009 for publication in 2011. 
Data from SEE cover only a limited children’s age group 
and vaccination status at other ages is not routinely 
collected in all federal states. Thus, they do not pro-
vide data for high interest target groups such as chil-
dren at two years of age and adults for longitudinal 
analysis at national level.
Figure 1


























Year 2002 2009 2002 2009 2002 2009 2002 2009 2002 2009 2002 2009 2002a 2009
Lowestb 93.4 93.1 83.0 92.7 85.2 89.6 53.7 80.0 89.4 93.9 23.2 85.8 – 15.1
Highestb 99.0 98.2 91.9 97.7 92.0 96.3 90.1 99.7 96.6 98.3 62.3 95.1 – 70.7
Hib: Haemophilus influenzae type b; WFS: western federal states; EFS: eastern federal states.
Vaccination coverage is given by vaccinated children per children presenting vaccination cards at school entry.  
a  Varicella vaccination was not yet recommended in 2002. In 2009, data on varicella vaccination were available from 15 federal states.
b  Lowest and highest federal state vaccination coverage values [8]. 
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The calculated coverage from SEE based on children 
presenting their vaccination cards is probably overes-
timated. Children not presenting the cards were less 
likely to have been vaccinated in an outbreak investiga-
tion [17] and had a higher prevalence of seronegativity 
in KiGGS [18] as compared to children with vaccination 
cards. 
Coverage as assessed by KiGGS was comparable to 
that of data from SEE in the same age groups, thus 
the respective results are validating each other. The 
huge benefits of examination surveys such as DEGS 
or KiGGS are their socio-demographic representative-
ness. This allows population based information on 
completeness and timeliness of vaccination in different 
groups defined by age and social status. By compar-
ing documented vaccinations with serological results 
and socio-demographic parameters, risks for not being 
vaccinated can be predicted and essential information 
for composing prevention strategies is gained. 
However, regular examination surveys are expensive, 
laborious, and complex and do not allow to estimate 
for recently recommended vaccinations. These short-
comings are partly overcome by telephone interview 
surveys. They are fast and flexible methods for col-
lecting data and enable decision makers, for instance, 
to respond quickly to inadequate immunisation rates. 
In addition, information on perceptions on vaccina-
tion issues can easily be gained. The balance between 
practicability and representativeness according to the 
aim of the survey may lead to limitations. A general 
shortcoming of interviewing people for their vaccina-
tion status might be the reliability of information as 
compared to the documented vaccinations in official 
documents [19]. 
Insurance refund claim data may compensate the limi-
tations of data from SEE. Moreover, if continuously 
collected, they can fill the gaps remaining between 
discrete population surveys. 
ASHIP data were the only available population based 
source for calculating vaccination coverage by age 
group and region shortly after introduction of varicella 
vaccines into the childhood immunisation programme 
in July 2004. Besides a growing acceptance of the rec-
ommendation and increasing coverage particularly in 
the recommended age group, the data showed that a 
considerable amount of vaccinations were given later 
than recommended and that the availability of vaccines 
as well as the reimbursement influenced the vaccine 
uptake [13]. In 2009, cumulative varicella vaccination 
incidence for children aged 4–6 years was in the same 
range as coverage calculated by SEE. Moreover, based 
on ASHIP data the vaccination coverage for children at 
two years of age will be routinely assessed and indi-
cate whether the primary courses of immunisation are 
completed as recommended. 
ASHIP data have been available since 2004, but vac-
cinations were also administered before that time, so 
only incident vaccinations per year since the time data 
collection started can be analysed. This leads to an 
underestimation of the true coverage, particularly in 
older age groups. Vaccination coverage, however, can 
be estimated for birth cohorts since ASHIP data col-
lection. These data are particularly useful to monitor 
uptake of vaccines which are newly introduced or rec-
ommended for other age groups than before. 
ASHIP data may be of limited representativeness for 
the total population as they are only related to statu-
tory health insured persons, while vaccination cover-
age of privately health insured persons may differ. 
Availability, validity and reliability of coverage esti-
mates based on data sources with an original purpose 
different from assessing vaccination status or cover-
age are highly dependent on a stable database and 
data structure. 
ASHIP data so far have been primarily used to answer 
specific questions that could not be answered by other 
data sources. Currently, these data are being estab-
lished as the official vaccination coverage of children 
aged 24 months in Germany. In addition, a comparison 
between data sources is being done to validate results 
whenever possible.
In summary, the described methods are of different 
public health relevance. Data from SEE allow to con-
tinuously analyse trends and regional differences in 
vaccination coverage related to childhood immunisa-
tion. With population surveys, target groups of immu-
nisation can be defined by age or socio-demographic 
characteristics, and insight on the acceptance of spe-
cific vaccines can be gained. In addition, vaccination 
programmes and campaigns can be assessed and 
Figure 2
Real-time monitoring of coverage with monovalent 
influenza A(H1N1)pdm09 vaccine by countrywide 
telephone interviews of individuals aged 14 years or older, 














































attitudes and behaviour towards vaccination exam-
ined. ASHIP data give rapid information on the com-
pliance with vaccination schedules but also about the 
general acceptance of immunisation programmes, in 
terms of vaccination coverage by region and age, and 
thus are helpful for identifying target age groups for 
(supplementary) immunisation.
The exploitation of further primary and secondary data 
sources for retrieving information on vaccination cov-
erage has been tested by the RKI with limited public 
health relevance. 
Immunising physicians were asked for the number of 
administered first and second doses of varicella and 
measles vaccines per month in a network of private 
doctors (sentinel). As the sentinel is not population 
based, coverage could not be calculated but trends in 
vaccine uptake were detected and related to different 
physician groups, regions and availability of vaccines 
[20]. As the documentation workload is high, attempts 
are ongoing to retrieve data automatically from the 
software systems used by physicians, but limiting fac-
tors are the variety of those systems together with data 
protection.
Commercial data on sale or prescription figures deliver 
trends in number of sold or prescribed vaccine doses 
over time by brand name, region and physician’s speci-
ality. Trend comparisons by region and by physicians’ 
speciality are possible. Moreover, with different vac-
cines available, insight is gained on preferred vaccine 
brands. These data show trends in vaccine uptake in 
total but not the coverage, as the number of immunised 
persons remains unknown. The completeness of indi-
vidual vaccination series cannot be assessed, particu-
larly if multiple doses are needed. 
In conclusion, complex health systems require complex 
approaches to gain data on vaccination coverage or on 
other vaccination issues. 
In the absence of immunisation registers several pri-
mary and secondary data sources have been explored 
by the RKI for assessing nationwide vaccination status 
and coverage. Different approaches for the utilisation 
of the various sources, either routinely or on specific 
demand, have been successfully implemented. Each of 
them has its strengths and limitations and they com-
plement one another, thus validating the information 
retrieved from different sources. 
Figure 3
One-dose varicella vaccination, annual rates for children aged one, two and three years, and cumulative rates for children 
aged from four to six years, Germany, 2004–2009
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The German experience with collecting vaccination 
coverage data at national level in a decentralised 
healthcare system, dominated by the private sector 
and in the absence of immunisation registers, might be 
of value for other countries with federal or otherwise 
decentralised healthcare systems.
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